Abstract:Glioblastoma (GBM) is the most lethal and aggressive form of brain cancer, with incredibly high recurrence rates and virtually no long-term survival. Despite our growing understanding of GBM at the molecular level, we still don't fully comprehend the molecular mechanisms driving recurrence in GBM. Current knowledge indicates that Glioma Stem Cells (GSCs) drive a resistant cell phenotype in GBM. Understanding the molecular events coordinated by GSCs leading to therapy-resistance can provide key advancements on how we treat recurrent GBM (rGBM). Mechanisms of GSC immune escape are considered fundamental to clinical GBM growth and recurrence. The cross talk between cancer cells and the immune system is now classified as a hallmark of cancer. The current dogma is that cancer cells, including GSCs, influence recruitment of immune-suppressive cell subsets to tumor tissue, however how subsets of GSCs mimic this immune-suppressive effect within the tumor microenvironment remains to be elucidated. Single-cell RNA sequencing analysis of GBM neurospheres revealed a previously unrecognized Oct4/Sox2high/FOXP3− cell subpopulation with high expression of TGFb1, CD39, CD73, PD-L1, and Galectin-1, a gene expression fingerprint typically associated with regulatory T cell (Tregs) and their immune suppressive functions within the tumor microenvironment. Bioinformatics analysis of public databases shows that the above-mentioned genes are enriched in the mesenchymal GBM subtype and highly correlated with TGFb type II receptor (TGFBR2) expression in clinical GBM. Mechanistically, we show that blocking TGFBR2 or XBP1 signaling, key intermediary of this process, counteracts the immune-suppressive phenotype of rGBM cells by restoring CD4 and CD8 tumor killing capacity and reversing exhaustion. By combining miRNA-based network analysis and advanced nanoparticle formulation for miRNA delivery we show that miR-16/124-3p effectively target all nodes of this immunosuppressive axis successfully blocking the immunosuppressive nature of rGBM cells. This research provides the first description of such neoplastic cells in any malignancy and has high potential translational impact since targeting these tumor cell subsets and their immunosuppressive mechanisms may be critical to the successful development of GBM immunotherapies. Citation Format: Hernando Lopez-Bertoni, Sophie Sall, Harmon Khela, Jack Korleski, Katherine Luly, Maya Johnson, Amanda Johnson, Jordan Green, John Laterra. GBM cells mimic regulatory T cell function to protect the CSC pool from immune surveillance in recurrent GBM [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl) nr B009.

TLR4 expression and functionality are downregulated in glioblastoma cells and in tumor-associated macrophages: A new mechanism of immune evasion?

TLR4 Signaling Promotes Immune Escape of Human Lung Cancer Cells by Inducing Immunosuppressive Cytokines and Apoptosis Resistance.

Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma

TLR agonists promote formation of Tertiary Lymphoid Structure and improve anti-glioma immunity

TLR2 Promotes Glioma Immune Evasion by Downregulating MHC Class II Molecules in Microglia

Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39

Immunohistochemical Characterization of Immune Infiltrate in Tumor Microenvironment of Glioblastoma

Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities

Immuno-oncology: are TAM receptors in glioblastoma friends or foes?

Tmic-03. Card9 Blockade Offers A New Opportunity To Reprogram Tumor-Associated Macrophages In Glioblastoma

Single-Cell Transcriptomics of Glioblastoma Reveals a Unique Tumor Microenvironment and Potential Immunotherapeutic Target Against Tumor-Associated Macrophage

Dissecting anti-tumor immunity in glioblastoma

Abstract LB297: Toll-like receptor 8 in tumor associated macrophages regulates miR-192-5p expression and drug resistance in neuroblastoma

Tmic-83. Aberrant Egfr Activation Supports Enhanced Tumor-Myeloid Crosstalk And Impairs Effector T Cell Infiltration And Function In Glioblastoma

Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression

Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma

Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma

Abstract B009: GBM cells mimic regulatory T cell function to protect the CSC pool from immune surveillance in recurrent GBM

Microglia and macrophages in glioblastoma: landscapes and treatment directions

Tumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities

Abstract 6442: Role of TWEAK-Fn14 axis in driving immunosuppression in glioblastoma multiforme